NMD treats A to Z

Why INKEF, Novo Seeds participated in NMD’s €38M series

The broad applicability of NMD Pharma ApS’s approach to treating neuromuscular conditions persuaded INKEF Capital to lead the company’s tranched €38 million ($46.6 million) series A round.

Fellow new investor Roche Venture Fund and

Read the full 340 word article

User Sign In